All In Biotech

NDA 214103 · Alnylam Pharms INC

Oxlumo

Lumasiran Sodium · Subcutaneous

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Apr 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Nov 23, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

7

3 Phase 3, 1 recruiting

FAERS reports

386

315 serious, 28 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 1, 2025.

OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients [see Clinical Pharmacology (12.1) , Clinical Studies (14.1 , 14.2 , 14.3) ] . OXLUMO is a HAO1 -directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients. ( 1 )

Mechanism: Lumasiran reduces levels of glycolate oxidase (GO) enzyme by targeting the hydroxyacid oxidase 1 ( HAO1 ) messenger ribonucleic acid (mRNA) in hepatocytes through RNA interference. Decreased GO enzyme levels reduce the amount of available glyoxylate, a substrate for oxalate production. As the GO enzyme is upstream of the deficient alanine: glyoxylate aminotransferase (AGT) enzyme that causes PH1, the mechanism of action of lumasiran is independent of the underlying AGXT gene mutation. OXLUMO is not expected to be effective in primary hyperoxaluria type 2 (PH2) or type 3 (PH3) because its...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 6, 2022 Supplement 3 · Efficacy OrphanLetterLabel
  • Nov 23, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
  • OXLUMO · LUMASIRAN SODIUM EQ 94.5MG BASE/0.5ML (EQ 94.5MG BASE/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Lumasiran" as an intervention, any sponsor and status, largest first.

All 7 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • renal transplant55
  • nephrolithiasis38
  • hospitalisation21
  • drug ineffective17
  • laboratory test abnormal17
  • urine oxalate increased17
  • acute kidney injury13
  • death13
  • intentional dose omission13
  • liver transplant13
  • product dose omission issue13
  • dialysis12

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20201
202119
202233
202366
202491
2025121
202655

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Oxlumo (Lumasiran Sodium)

2024 spending

$6.4M

Beneficiaries

11

42 claims

Per beneficiary

$578,402

$117,822.65 per unit

View as table
YearSpending
2020$0
2021$0
2022$1,763,404
2023$0
2024$6,362,423

Part B: Oxlumo (Lumasiran Sodium) · HCPCS J0224

2024 spending

$3.7M

Beneficiaries

n/a

44 claims

Per beneficiary

n/a

2024 ASP limit $318.51 per unit

View as table
YearSpending
2020$0
2021$0
2022$2,607,112
2023$3,511,438
2024$3,667,203

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8 on PubMed

Sponsor: Alnylam Pharmaceuticals

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.